Gilead Sciences has set the wholesale price for its new once-a-day HIV/AIDS pill: It’s $28,500 a year. That works out to $78 per pill.
Earlier this year, the Clinton Foundation reported that it has secured generic drugs for delivering combination HIV/AIDS therapy in the developing world for $200 per year. Of course, that requires taking multiple pills several times a day, which makes compliance more difficult.
Gilead’s four-drug combo pill, taken just once a day, clearly is an innovation. But is it really 140 times more valuable than a generic approach? Perhaps the U.S. health care system should sign up for help from the Clinton Foundation.
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Merrill Goozner is an award-winning journalist and author of "The $800 Million Pill: The Truth Behind the Cost of New Drugs" who writes regularly at Gooznews.com.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.